|
11.
|
|
9 p, 698.5 KB |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib : A GIMEMA, ERIC and UK CLL FORUM study
/
Cuneo, Antonio (St. Anna University Hospital) ;
Follows, George (Cambridge University Hospitals NHS Foundation Trust (Anglaterra)) ;
Rigolin, Gian Matteo (St. Anna University Hospital) ;
Piciocchi, Alfonso (Italian Group for Adult Hematologic Diseases (GIMEMA)) ;
Tedeschi, Alessandra (Niguarda Cancer Center) ;
Trentin, Livio (University of Padua) ;
Perez, Angeles Medina (Hospital Costa del Sol (Marbella)) ;
Coscia, Marta (University of Turin) ;
Laurenti, Luca (Policlinico A. Gemelli) ;
Musuraca, Gerardo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)) ;
Farina, Lucia (Fondazione IRCCS Istituto Nazionale Tumori) ;
Delgado, Alfredo Rivas (Hospital Clínic i Provincial de Barcelona) ;
Orlandi, Ester Maria (Fondazione IRCCS Policlinico San Matteo) ;
Galieni, Piero (Ospedale C. e G. Mazzoni) ;
Mauro, Francesca Romana ("Sapienza" University) ;
Visco, Carlo (San Bortolo Hospital) ;
Amendola, Angela (San Carlo Hospital) ;
Billio, Atto (Azienda Sanitaria dell'Alto Adige) ;
Marasca, Roberto (University of Modena and Reggio Emilia) ;
Chiarenza, Annalisa (Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele) ;
Meneghini, Vittorio (University Hospital) ;
Ilariucci, Fiorella (Arcispedale S. Maria Nuova) ;
Marchetti, Monia (Cardinal Massaia Hospital) ;
Molica, Stefano (Azienda Ospedaliera Pugliese Ciaccio) ;
Re, Francesca (University Hospital) ;
Gaidano, Gianluca (Università del Piemonte Orientale Amedeo Avogadro) ;
Gonzalez, Marcos (Hospital Universitari IBSAL i CIBERONC) ;
Forconi, Francesco (University Hospital National Health Service Trust) ;
Ciolli, Stefania (Careggi University Hospital (Florència, Itàlia)) ;
Cortelezzi, Agostino (University of Milan) ;
Montillo, Marco (Niguarda Cancer Center) ;
Smolej, Lukas (University Hospital) ;
Schuh, Anna (Oxford University Hospitals NHS Foundation Trust) ;
Eyre, Toby A. (Oxford University Hospitals NHS Foundation Trust) ;
Kennedy, Ben (University Hospitals of Leicester NHS Trust) ;
Bowles, Kris M. (Norwich Medical School) ;
Vignetti, Marco (Italian Group for Adult Hematologic Diseases (GIMEMA)) ;
De La Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Foà, Robin ("Sapienza" University) ;
Ghia, Paolo (IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University) ;
Universitat Autònoma de Barcelona
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. [...]
2018 -  10.3324/haematol.2018.189837
Haematologica, Vol. 103 Núm. 7 (march 2018) , p. 1209-1217
|
|
|
12.
|
|
19 p, 600.4 KB |
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
/
Barrientos, Jacqueline C. (Zucker School of Medicine at Hofstra/Northwell) ;
O'Brien, Susan (University of California Irvine) ;
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Kay, Neil E. (Mayo Clinic) ;
Reddy, Nishitha M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Tam, Constantine (Peter MacCallum Cancer Centre and St Vincent's Hospital) ;
Mulligan, Stephen (Royal North Shore Hospital) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Devereux, Stephen (King's College Hospital NHS Foundation Trust) ;
Pocock, Christopher (East Kent Hospitals University) ;
Robak, Tadeusz (Medical University of Lodz) ;
Schuster, Stephen J. (Perelman Center for Advanced Medicine) ;
Schuh, Anna (University of Oxford) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Bloor, Adrian (The Christie Clinic) ;
Dearden, Claire (The Royal Marsden Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cull, Gavin (Sir Charles Gardiner Hospital) ;
Hamblin, Mike (Colchester Hospital) ;
Jones, Jeffrey A. (The Ohio State University Comprehensive Cancer Center) ;
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Suzuki, Samuel (Pharmacyclics LLC. an AbbVie Company) ;
Hsu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James University Hospital) ;
Universitat Autònoma de Barcelona
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. [...]
2018 - 10.1016/j.clml.2018.08.007
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 12 (december 2018) , p. 803-813.e7
|
|
|
13.
|
|
9 p, 1.3 MB |
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies
/
Robak, Tadeusz (Medical University of Lodz) ;
Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Barr, Paul M. (University of Rochester Cancer Center) ;
Owen, Carolyn (University of Calgary) ;
Bairey, Osnat (Tel Aviv University) ;
Hillmen, Peter (St. James's Institute of Oncology) ;
Simpson, David (North Shore Hospital) ;
Grosicki, Sebastian (Silesian Medical University) ;
Devereux, Stephen (King's College Hospital NHS Foundation Trust) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Quach, Hang (St. Vincent's Hospital) ;
Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ;
Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ;
Stevens, Don A. (Norton Cancer Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gill, Devinder S. (Princess Alexandra Hospital) ;
Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Gribben, John G. (Queen Mary University of London) ;
Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Kipps, Thomas J (University of California San Diego) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410
|
|
|
14.
|
|
25 p, 1.7 MB |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
/
O'Brien, Susan (University of California) ;
Hillmen, Peter (St. James University Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Barr, Paul M (University of Rochester Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ;
Hess, Georg (Universitats Medizin Mainz) ;
Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ;
Vermeulen, Jessica (Janssen Research & Development) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research & Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ;
Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ;
Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ;
Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15
|
|
|
15.
|
|
18 p, 4.4 MB |
TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype
/
Ramos-Campoy, Silvia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Kamaso, Joanna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Beà, Sílvia (Centro de Investigación Biomédica en Red de Cáncer) ;
Bougeon, Sandrine (Lausanne University Hospital) ;
Larráyoz, María José (Universidad Pública de Navarra) ;
Costa, Dolors (Centro de Investigación Biomédica en Red de Cáncer) ;
Parker, Helen (University of Southampton) ;
Rigolin, Gian Matteo (St. Anna University Hospital) ;
Blanco, María Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Collado, Rosa (Consorcio Hospital General Universitario) ;
Ancín, Idoya (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Salgado, Rocío (Fundación Jiménez Díaz) ;
Moro-García, Marco A. (Hospital Universitario Central de Asturias) ;
Baumann, Tycho (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gimeno, Eva (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Calasanz, M.J (Universidad Pública de Navarra) ;
Cuneo, Antonio (Hematology Section. St. Anna University Hospital) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Oscier, David (Royal Bournemouth Hospital) ;
Haferlach, Claudia (MLL Munich Leukemia Laboratory) ;
Strefford, Jonathan C (University of Southampton) ;
Schoumans, Jacqueline (Lausanne University Hospital) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
Chromothripsis (cth) has been associated with a dismal outcome and poor prognosis factors in patients with chronic lymphocytic leukemia (CLL). Despite being correlated with high genome instability, previous studies have not assessed the role of cth in the context of genomic complexity. [...]
2022 - 10.3390/cancers14153715
Cancers, Vol. 14 Núm. 15 (august 2022) , p. 3715
|
|
|
16.
|
|
14 p, 1.1 MB |
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
/
Kipps, Thomas J. (UC San Diego Moores Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute) ;
Barr, Paul M. (University of Rochester) ;
Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ;
O'Brien, Susan M. (University of California) ;
Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque) ;
Hillmen, Peter (University of Leeds) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Stilgenbauer, Stephan (University of Ulm) ;
Chanan-Khan, Asher A. (Mayo Clinic Cancer Center) ;
Mahler, Michelle (Janssen Research and Development) ;
Salman, Mariya (Janssen Research and Development) ;
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Balasubramanian, Sriram (Janssen Research and Development) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Londhe, Anil (Janssen Research and Development) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research and Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Hallek, Michael (University of Cologne) ;
Universitat Autònoma de Barcelona
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). [...]
2019 - 10.1016/j.clml.2019.07.004
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 11 (november 2019) , p. 715-722.e6
|
|
|
17.
|
|
7 p, 267.3 KB |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials
/
Allan, John N. (Weill Cornell Medicine) ;
Shanafelt, Tait (Stanford University Medical Center) ;
Wiestner, Adrian (National Heart, Lung, and Blood Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
O'Brien, Susan M. (University of California Irvine) ;
Li, Jianling (Pharmacyclics LLC) ;
Krigsfeld, Gabriel (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ;
Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 - 10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953
|
|
|
18.
|
|
18 p, 2.5 MB |
The EHA Research Roadmap : Malignant Lymphoid Diseases
/
Dreyling, Martin (LMU Hospital (Alemanya)) ;
André, Marc (Université Catholique de Louvain (bèlgica)) ;
Gökbuget, Nicola (Goethe University (Alemanya)) ;
Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ;
Jerkeman, Mats (Skåne University and Lund University (Suècia)) ;
Gribben, John (Queen Mary University of London (Regne Unit)) ;
Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ;
Morel, Pierre (CHU Amiens Picardie (França)) ;
Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ;
Fox, Christopher (University of Nottingham (Regne Unit)) ;
Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ;
Aurer, Igor (University of Zagreb (Zagreb)) ;
Bödör, Csaba (Semmelweis University (Hongria)) ;
Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ;
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ;
Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ;
Davies, Andrew (University of Southampton (Regne Unit)) ;
de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ;
Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ;
Federico, Massimo (GVM Care & Research (Itàlia)) ;
Gaulard, Philippe (Hôpital Henri Mondor (França)) ;
Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ;
Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ;
Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ;
Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ;
Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ;
Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ;
Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ;
Lenz, Georg (Medical University Hospital Münster (Alemanya)) ;
Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ;
Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ;
Moreau, Philippe (University Hospital Hotel-Dieu (França)) ;
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Nadel, Bertrand (Aix Marseille Univ (França)) ;
Okosun, Jessica (Queen Mary University of London (Regne Unit)) ;
Owen, Roger (St James's Institute of Oncology (Regne Unit)) ;
Pospisilova, Sarka (University Hospital Brno (Txèquia)) ;
Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Robak, Tadeusz (Medical University of Lodz (Polònia)) ;
Spina, Michelle (National Cancer Institute (Itàlia)) ;
Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ;
Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ;
Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ;
Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ;
Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ;
Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ;
Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ;
Salles, Gilles (Weill Cornell Medicine (Estats Units)) ;
Universitat Autònoma de Barcelona
2022 - 10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)
|
|
|
19.
|
|
13 p, 1.6 MB |
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial
/
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ;
Demirkan, Fatih (Dokuz Eylul University (Turquía)) ;
Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ;
Anz, Bertrand (Tennessee Oncology (Estats Units)) ;
Larratt, Loree (University of Alberta Hospital (Canadà)) ;
Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ;
Novak, Jan (Charles University (Txèquia)) ;
Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Gribben, John G. (Barts Cancer Institute) ;
Kwei, Kevin (Pharmacyclics LLC) ;
Dai, Sandra (Pharmacyclics LLC) ;
Hsu, Emily (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Flinn, Ian W. (Sarah Cannon Research Institute) ;
Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120
|
|
|
20.
|
|
11 p, 1.4 MB |
Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
/
Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ;
Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ;
Robak, Tadeusz (Medical University of Lodz) ;
Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Department of Hematology. Rabin Medical Center) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ;
Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ;
Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ;
Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ;
Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ;
Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
